Abstract A wide range of support is available to help smokers to quit and to aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion. Despite the efficacy of these, there is a continual need to diversify the range of medications so that the needs of tobacco users are met. This paper compares the first-line smoking cessation medications with (1) two variants of these existing products: new galenic formulations of varenicline and novel nicotine delivery devices; and (2) 24 alternative products: cytisine (novel outside Central and Eastern Europe), nortriptyline, other tricyclic antidepressants, electronic cigarettes, clonidine (an anxiolytic), other anxiolytics (e.g. buspirone), selective serotonin reuptake inhibitors, supplements (e.g. St John's wort), silver acetate, Nicobrevin, modafinil, venlafaxine, monoamine oxidase inhibitors (MAOIs), opioid antagonists, nicotinic acetylcholine receptor (nAChR) antagonists, glucose tablets, selective cannabinoid type 1 receptor antagonists, nicotine vaccines, drugs that affect gamma-aminobutyric acid (GABA) transmission, drugs that affect N-methyl-Daspartate (NMDA) receptors, dopamine agonists (e.g. levodopa), pioglitazone (Actos; OMS405), noradrenaline reuptake inhibitors and the weight management drug lorcaserin. Six 'ESCUSE' criteria-relative efficacy, relative safety, relative cost, relative use (overall impact of effective medication use), relative scope (ability to serve new groups of patients) and relative ease of use-are used. Many of these products are in the early stages of clinical trials; however, cytisine looks most promising in having established efficacy and safety with low cost. Electronic cigarettes have become very popular, appear to be efficacious and are safer than smoking, but issues of continued dependence and possible harms need to be considered.
Introduction
Despite significant declines in the prevalence of tobacco use in many countries over the past couple of decades [1] , smoking remains the leading avoidable cause of premature death worldwide, accounting for more than 5 million deaths per year [2] . Smoking is also responsible for multiple morbidities, including cancer, heart disease, stroke, emphysema, bronchitis, chronic airway obstruction and diabetes [3] .
Bupropion, nicotine replacement therapy (NRT) and varenicline are licensed as first-line smoking cessation aids in Australia, the European Union and North America, and are recommended in many national guidelines [4] . There is substantial evidence from clinical trials, population studies and routine clinical data for the efficacy of these medications for cessation and the use of NRT for harm reduction [5] [6] [7] [8] [9] [10] .
Yet, some smokers find these three traditional medications unacceptable [11] , and in many countries, they are not affordable [12] . This paper aims to review alternative medications that have been assessed for smoking cessation and harm reduction, alongside the three first-line products, using six 'ESCUSE' criteria that we propose: relative efficacy, relative safety, relative cost, relative use (overall impact of effective medication use), relative scope (ability to serve new groups of patients) and relative ease of use.
ESCUSE Criteria

Relative Efficacy: Is the Product More Efficacious than Existing Drugs?
Efficacy is the extent to which an intervention does more good than harm in ideal circumstances (usually a clinical trial), i.e. does the drug work? We are often interested in whether novel treatments have greater or similar efficacy to that of established pharmacotherapy. However, efficacy is often hard to address for novel treatments, because of the absence of long-term clinical trials. Indeed, up to 97 % of data on the efficacy of medication is based on short-term surrogate end-points [13] and, even where high-quality clinical data are available, medicines sometimes do not perform as expected in everyday clinical practice [14] . This is because effectiveness-the ability of a drug to produce a beneficial effect in real-world settings-is highly dependent on compliance with the drug routine. However, the effect of delivery in routine clinical settings is generally possible to assess only once a drug is licensed for its indication. Consequently, where information on efficacy and effectiveness are unavailable, we will draw conclusions from research on other drugs with similar pharmacotherapy profiles. For example, both cytisine and varenicline act as nicotinic receptor partial agonists, while NRT and electronic cigarettes (e-cigarettes) are based on the principle of providing pure nicotine without the toxic constituents of tobacco.
Relative Safety: Is the Product Safer than Existing Drugs?
The safety profile of a drug is often viewed as a top priority in evaluating the possible public health impact of a novel treatment. A product that is equally as effective as an existing product but is deemed less dangerous will likely have an overall public health benefit, while a product that is equally effective but is deemed more dangerous may have a negative public health impact [15] . Side effects can range from being mild and short-lived to being severe and longlasting; the latter need to be minimized or ideally removed in products coming to the market. Generally, evidence for the safety profile of a drug comes from clinical trials and population surveillance. However, as a number of novel treatments have not been evaluated long-term, safety assurances necessarily rely on expert judgment and pharmacological profiles, and they should be updated regularly as new information emerges. For instance, research in the USA shows that postmarketing surveillance generally identifies serious drug reactions only at a median of 3 years after approval [16] .
Relative Cost: Is the Product Cheaper than Existing Drugs?
The cost of a new drug should always be considered in the overall assessment of its place in the treatment of dependence. Around the world, health care service budgets are increasingly under strain; thus, drugs that are deemed effective may be available only if they come at a suitable cost. Indeed, cost effectiveness is viewed as the 'fourth hurdle' among the criteria of drug regulation and licensing decisions, given that the cost of new drugs is nearly always significantly higher than the costs of the drugs they aim to replace [17] .
Relative Use: Will the Product Increase the Number of Patients Using Some Form of Effective Medication?
Increased public health benefits at a population level from new treatments will occur when either (1) smokers switch to a more effective novel product; or (2) a novel product entices smokers not using pharmacotherapy to use effective medication. Thus, there is a need to assess whether the presence of a drug in the market will increase the overall use of pharmacotherapy. Prior to the drug's availability, informed hypotheses can be made, but it is not possible to ascertain its true impact. Even once the drug is in use at a population level, long-term surveillance will be required, since initial effects may not be maintained [18] . Often the aim of novel treatments is to serve a group of patients who are not adequately served by existing medications. Medications regularly have contraindications for at-risk populations and are not equally available in all countries. For example, patients who are pregnant, suffer from cardiovascular disease and/or have psychiatric conditions are often warned against condition-unrelated pharmacotherapy because of the possibility of adverse effects. Novel treatments can also be required to meet individual preferences for the delivery method, potency and action of a drug [11, 19] . There have been increasing moves towards personalization and stratification of treatment, including 'mutually agreed tailoring', which involves management of conditions by incorporating specific needs and experiences with clinical judgment to decide on drug routines [20] [21] [22] [23] .
Relative Ease: Is the Product Easier to Take than Existing Drugs?
Fewer than half of all drugs are taken as recommended [24] . Consequently, simplifying a drug routine can be an important step in promoting adherence. Simplification can involve reducing dose complexity (e.g. from four times daily to once daily), changing the mode of delivery (e.g. from an injection to a tablet) and helping patients to integrate the regimen into their daily lives [24] .
First-Line Treatments for Smoking Cessation and Harm Reduction
NRT was introduced in 1978 in Switzerland as a chewing gum formulation (and then in Canada in 1979 and in the UK in 1980), followed by the nicotine patch in the USA in 1992 [25] . The basis of the development of NRT was evidence that the main addictive component of cigarettes is nicotine [26] [27] [28] , but that it is the other thousands of chemicals resulting from cigarette combustion that cause the excess mortality and morbidity [29, 30] . Over the next 30 years, the market expanded rapidly with the development of faster-acting products, such as the nicotine inhalator, nicotine lozenges, nicotine nasal spray, fastdissolving oral nicotine strips and nicotine mouth spray [31, 32] . Variations also became available in a number of countries, including high-strength patches [33] , rapid-delivery gums [34] and mini-lozenges, which dissolve more quickly than standard lozenges [35] . These products were initially licensed only for smoking cessation but have subsequently been recommended in a number of countries, including the UK, for harm reduction [36] . The next first-line treatment introduced to the market was bupropion. This atypical antidepressant was proposed as a smoking cessation aid by Ferry in 1989 [37] following the observation that smokers taking it for depression stopped smoking spontaneously. However, it was not approved as a smoking cessation aid until 1997, after a series of manufacturer-funded clinical trials [37] . Bupropion, marketed under the trade names Zyban and Wellbutrin, is thought to help smokers to quit through its ability to inhibit neuronal reuptake of dopamine, noradrenaline (norepinephrine) and serotonin/5-hydroxytryptamine (5-HT) [38] .
The third first-line treatment, varenicline (Chantix, Champix)-a nicotinic acetylcholine receptor (nAChR) partial agonist and a synthetic derivative of the alkaloid cytisine-entered the UK and US markets in 2006 [39, 40] . It was hypothesized that a partial agonist of nAChRs would lead to a moderate and sustained increase of mesolimbic dopamine levels, thus reducing withdrawal symptoms. At the same time, varenicline was argued to shield a smoker from dependence-maintaining increases in neurotransmitters because of its higher affinity for nAChRs than the native ligand, nicotine, and therefore reduce the rewarding effects of smoked tobacco [41] . Table 1 applies the ESCUSE criteria to these three firstline treatments and forms the baseline for comparing novel pharmacotherapies. Varenicline appears to be the most effective of the three medications but has the greatest number of apparent side effects and contraindications. NRT offers smokers greater variety and is substantially cheaper but often is not adhered to or used correctly, while bupropion may be a suitable treatment for individuals with co-morbid depression diagnoses but is also associated with an increased seizure risk.
Other Pharmacotherapies for Smoking Cessation and Harm Reduction
Over the past couple of decades, attempts have been made to devise alternative novel pharmacotherapies either based on the first-line treatments or that work via alternative mechanisms. These products are reviewed below, starting with variants of existing products and then products with novel mechanisms, in order of their likely efficacy. [361] . NRT has also been demonstrated to be effective at a population level [347] . NRT products can also be combined to increase effectiveness, e.g. a slow-acting transdermal product and a fast-acting non-transdermal product [32] Many smokers perceive NRT to be less satisfying than smoking cigarettes, in part because it fails to fully address the reinforcing effects of smoking, e.g. the handto-mouth movement [229] . However, this does mean that NRT has a low liability for abuse and a low dependence potential [362] . In clinical trials, the major side effects usually reported have been hiccups (with gum and sublingual tablets), gastrointestinal disturbances (with gum), jaw pain (with gum), dental problems (with gum and sublingual tablets), nasal irritation (with a spray), and skin sensitivity (with patches). Serious adverse events are sparse [361] , and NRT does not appear to perpetuate cardiac disease [363] [364] [365] Bupropion Bupropion significantly increases long-term cessation [83] . It appears to be equally effective for both men and women and for those with and without a diagnosis of depression [83, 375] . Outside clinical trials, bupropion has been shown to induce higher quit rates than NRT alone [376, 377] . There is also some evidence that it may be capable of minimizing the weight gain associated with smoking cessation [378] Although bupropion has been associated with mild side effects, including dry mouth and insomnia, very few users experience adverse effects [38, 379] . Following bupropion's launch in 2000, the media reported a number of deaths in smokers using bupropion, but postmarketing surveillance in the UK found only 60 fatal events over 2 years among 540,000 smokers, and most of these were caused by an underlying smoking-related disease [379] . Overall, the benefit of bupropion was deemed to outweigh any possible side effects, and so smoking cessation guidelines in both the UK and the USA recommend it as a safe effective medication for those who wish to use it [19, 380] In the UK, the cost of bupropion per lifetime quitter has been estimated at between £960 (US$1400) and £1800 (US$2600), which is roughly equivalent to estimates in the USA [381, 382] . Despite its higher cost, there is some evidence that bupropion is more cost effective than NRT [383] , with an incremental cost per quality-adjusted life-year gained (QALY) of approximately one third less than the cost of NRT [384] Prior to the introduction of bupropion, the only licensed pharmacotherapy available to help smokers quit was NRT. However, despite initial promise, bupropion has failed to reach dominance, taking less than a 5 % share of total prescribing for smoking cessation in England [385] A reduced dose of bupropion may be required in elderly patients, people with diabetes and smokers with renal or hepatic impairment [38] . [76, 389] . It is also the only drug that has proven long-term efficacy in smokers with chronic obstructive pulmonary disease [390, 391] , and is efficacious for patients with psychiatric disorders [392] . The introduction of varenicline in the USA appeared to coincide with a net overall increase in both aided and unaided attempts to quit smoking [40] , although a similar effect was not seen in the UK [56, 67] . Evidence is also emerging that greater benefits may be obtained through combination use with bupropion and that such concurrent therapy is well tolerated [359, 393] Its safety in patients with cardiovascular disease has been questioned. 
Variants of Existing Products
Novel Nicotine Delivery Products
Because of the unpleasant taste and side effects of traditional NRT products [42, 43] , a number of alternative devices have been proposed. These included the single-use nicotine straw, which contains small beads and drops of nicotine [44] ; nicotine pouches, which contain flavoured nicotine granules [45] ; pulmonary nicotine delivery devices (in the form of nebulizers, pressurized metered-dose inhalers and other non-metered-dose inhalers), which deliver nicotine into the lungs [46] ; carbon nanotubes, which are transdermal and have gate-keeping properties [47] ; the nicotine cannon-a wide-bore nicotine delivery device, which holds up to five inhalator cartridges [48] ; and nicotine films, which attempt to combine the properties of both oral and transdermal products, i.e. increased speed of nicotine delivery, flexibility in application and bi-phasic nicotine release [49] . Most remain in early stages of development, with the exception of the nicotine pouch, which is available in some countries, including Sweden, while work on the nicotine straw has become dormant for unknown reasons [32] .
Relative Efficacy Although there is currently limited evidence for the efficacy of these novel nicotine delivery devices in relation to smoking cessation, preliminary data suggest that they may be as effective as, or more effective than, licensed NRT in reducing withdrawal symptoms and desire for cigarettes [32] . Some of the products deliver nicotine as fast as, or faster than, licensed NRT and are judged to be more enjoyable and satisfying to use. In a repeated-measures crossover trial, the nicotine cannon alleviated urges to smoke and was deemed to be more acceptable by users, while a small randomized trial of 24 smokers found that plasma levels of nicotine peaked between 1 and 2 h after using a nicotine straw, which is comparable to findings with other NRTs [44, 48] . However, the nicotine straw is likely to be ineffective when used in combination with beverages with lower pH values [43] . Nebulizers and nicotinic inhalers have also been shown to reduce the desire for cigarettes [46, 50] . Carbon nanotubes, through their ability to control the flow of nicotine across the membrane, may overcome many of the limitations of the traditional patches, allowing programmable variable drug delivery rates [51] .
Relative Safety Devices that deliver nicotine through the bronchial alveoli, as is achieved by cigarettes, may have greater abuse potential [44] . Although many of the products, including the nicotine straw, are well tolerated [52] , they have mild side effects, particularly the pulmonary delivery devices, which are aversive at high doses [32] . A recent systematic review reported that nebulizers elicit dose-dependent coughs [53] . Dose-dependent reflux interruption of smooth inspiration has also been reported with metered-dose inhalers in clinical trials [53] . However, some novel products may have more favourable side effects than established NRT, which can cause hiccups, nausea and local irritation.
Relative Cost Although adaptations of an existing product have the advantage of being potentially cheaper and easier to produce and license than the other treatments discussed below, some of these products may be more expensive (e.g. the nicotine cannon, which requires multiple inhalator cartridges) [48] .
Relative Use None of the products, with the exception of nicotine pouches, are currently available to smokers. However, if they were to be licensed, it is likely that they would increase overall use of non-tobacco nicotine-containing products, according to evidence that bringing new nicotine delivery devices into the market results in more smokers trying pharmacological aids [54] . Previous studies have suggested that novel products do not simply substitute for existing ones [55, 56] .
Relative Scope These products may be particularly suitable for users who find traditional NRT products ineffective or unacceptable [57] . However, they are likely to be contraindicated for populations similar to those with contraindications to traditional NRT products and may, in the case of pulmonary delivery devices, have a greater number of side effects.
Relative Ease of Use Use of these nicotine delivery devices is similar to that of traditional NRT products. For example, the 50 mg nicotine cannon (5 9 10 mg cartridges) and pulmonary delivery devices can be used as needed, while nicotine straws in 4, 8 or 12 mg doses can be used every 1-2 h.
New Galenic Formulations of Varenicline
Galenic formulations of varenicline have been considered in order to improve the efficacy and acceptability of the traditional varenicline formulation. Galenic formulation is the process of medication preparation and compounding in order to optimize both the rate and the extent of medication absorption. To date, three new galenic formulations of varenicline have been proposed and are currently being tested in randomized controlled trials.
The first is a free-base patch, which aims to deliver varenicline transdermally. The second is a controlled-release tablet formulation. This aims to slow the rate of release of varenicline in the gastrointestinal tract and extend the absorption phase [58] . This has been achieved using an osmotic controlled-release system, where a tablet core made from varenicline, mannitol, microcrystalline cellulose and dicalcium phosphate is coated with a porous and semipermeable coating. As water enters the coating and the core, the drug is dissolved and released into the bloodstream [59] . Two clinical trials (ClinicalTrials.gov study IDs NCT00731562 and NCT00527150 [completed in 2010] ) have assessed the absorption rate, pharmacokinetics, safety and tolerability of a single dose and escalating multiple oral doses of varenicline controlled-release tablets. A further clinical trial (ClinicalTrials.gov study ID NCT00741884), which planned to evaluate the safety and efficacy of three doses of controlled-release varenicline specifically for smoking cessation, was terminated prior to participant enrolment.
The third is a free-base solution, which can be applied to the skin in the form of an ointment, cream or lotion. A spray form has also been proposed, which would result in a more concentrated amount of the active ingredient on the skin because of evaporation. In addition to varenicline, the sprayable liquid comprises a phospholipidic gel-forming agent, ethanol, phosphate buffer and distilled water [60] . A clinical trial assessing the absorption of varenicline into the body from a varenicline solution was completed in 2009 (ClinicalTrials.gov study ID NCT00774605).
Relative Efficacy The results from the clinical trials have yet to be released; however, these novel formulations are likely to be as efficacious as-if not more efficacious than-traditional formulations [41] . Slow-release drug formulations often lead to better compliance and maintenance of plasma levels of the drug in therapeutic ranges [61] . The free-base patch form of varenicline will have the advantage of administering a steady infusion of the drug over an extended period of time, and adverse effects or therapeutic failure, which are often associated with intermittent dosing, will be avoided [62] . Free-base varenicline solution has been shown to reduce nicotine administration in rats dose dependently [63] .
Relative Safety The reduced rate of passage and absorption of the controlled-release tablet formulation aims to reduce side effects associated with varenicline, such as nausea [58] . Previous studies have shown that controlledrelease bupropion reduces the incidence of side effects leading to treatment discontinuation [64] . There is also evidence to suggest that controlled-release medications are less likely to be abused or misused [61] . Free-base patches have an even better safety profile, in that drug input can be terminated at any point by removal of the patch. However, they may lead to other side effects, including skin irritation [62] .
Relative Cost New galenic formulations are likely to be similar in price to traditional formulations of varenicline [65] , which currently costs around £165 (US$240) for 12 weeks [66] .
Relative Use The introduction of traditional formulations of varenicline in the USA resulted in a net increase in use of stop-smoking medications [40, 67] . However, since speculation arose about associations of varenicline with cardiovascular disease and suicidal ideation, prescription rates have fallen [68] [69] [70] . Unless such concerns are reduced, new galenic formulations may not have a dramatic impact on overall effective mediation use.
Relative Scope New galenic formulations may be suitable for those patients who have failed with other medications but experience side effects with the traditional formulations of varenicline.
Relative Ease of Use Controlled-release varenicline is in an oral drug form, which has the notable advantage of easy administration, and free-base patches may improve compliance by simplifying the medical routine [62] .
Alternative Products with Efficacy or Likely Efficacy
Cytisine
Cytisine (marketed as Tabex) is a plant-based alkaloid found in members of the Leguminosae family. Like varenicline, it acts as a partial agonist of nAChRs and has a half-life of around 4.8 h [71] . However, it would be wrong to suggest that this is a novel product worldwide. In fact, cytisine was developed as a treatment for tobacco dependence in Bulgaria in the early 1960s, and it is still commercially available in Central and Eastern Europe.
Relative Efficacy Cytisine's initial distribution was restricted by early studies showing that it had poor absorption rates and limited effects on the brain [72, 73] . However, the 2006 positive review by Etter [74] and licensing of varenicline, which has a similar mechanism of action, brought renewed attention. Since then, a number of studies have demonstrated its efficacy. A pragmatic, openlabel, non-inferiority trial with 1310 adult daily smokers noted that when combined with behavioural support, cytisine promoted continuous abstinence at 6 months to a greater extent than NRT, while a Cochrane systematic review reported that cytisine was four times as effective as placebo [75, 76] .
Relative Safety Cytisine appears to have a greater number of side effects than NRT, including gastrointestinal problems [77] , headaches, irritability, nausea, constipation and tachycardia [74] . Cytisine is also contraindicated for people with arterial hypertension and advanced atherosclerosis [74] .
Relative Use Cytisine is more cost effective than currently licensed products, and so it may be pivotal in helping to reduce social inequalities in smoking cessation [78] . The cost of a course of cytisine is generally about 10-20 % of that of varenicline (US$12 for full treatment) [78] . However, its development is hindered by the substantial investment that would be required to meet licensing requirements and, as a result, its advantage of being low cost may be lost in the process [79] .
Relative Scope Given evidence that decreasing the price of treatments increases overall use of medication for smoking cessation [54] , its presence in the worldwide market may increase overall use of effective medications. The evidence suggests that there is a higher prevalence of use of smoking cessation aids in Eastern Europe, where cytisine is licensed as a smoking cessation aid, than in Southern Europe [80] .
Relative Scope Because of its low cost, cytisine is likely to be beneficial for patients in developing countries and to be beneficial for those with contraindications to other medications. Indeed, combined use of nicotinic partial agonists and NRT is well tolerated [81] . It is derived naturally from the seeds of the plant Cytisus laborinum, which may be an important characteristic for smokers who do not wish to use a synthesized drug.
Relative Ease of Use The most common dosage is 2-6 cytisine 1.5 mg tablets per day, which is higher than the oral dosage of varenicline but lower than the recommended dosage of non-transdermal nicotine products. For those patients who do not like oral administration, cytisine is also available as a film, which is placed between the gum and lip, and dissolves over time [74] .
Nortriptyline
There was a rapid expansion of research into other antidepressants for smoking cessation following the advent of bupropion, with nortriptyline becoming a popular second-line treatment in many countries [82] . Nortriptyline is a tricyclic antidepressant, named after its chemical structure, which contains three rings of atoms.
Relative Efficacy Nortriptyline has similar efficacy to both bupropion and licensed NRT [83] . Six placebo-controlled trials have shown that nortriptyline doubles quit rates [84] . A recent pragmatic randomized controlled trial of 901 smokers reported that prolonged abstinence at 6 months was 34 % more likely in those receiving nortriptyline plus NRT than in those receiving placebo plus NRT [85] . In this trial, nortriptyline was also found to reduce depression and anxiety, but urges to smoke did not differ between the groups.
Relative Safety The effects of nortriptyline on dopaminergic and adrenergic systems are believed to be similar to those of bupropion, but nortriptyline tends to have greater side effects. These include dry mouth, urinary retention, constipation, sexual difficulties and seizure risk [84] . When nortriptyline is used in combination with NRT, excessive sweating and shaking have been reported [85] . Concerns have also been raised regarding the use of tricyclics for the treatment of depression, because of the possibility of toxicity in the event of an overdose.
Relative Cost Nortriptyline is proposed to be much cheaper than bupropion. For example, in the Netherlands, 1 month of treatment with bupropion costs around €72 (US$80) compared with €12 (US$14) for nortriptyline [86] . Nortriptyline also appears to have equivalent cost effectiveness, supporting its utility [87] .
Relative Use Nortriptyline has become a popular second-line treatment for smoking cessation in many countries, including New Zealand [88] .
Relative Scope Like bupropion, nortriptyline is likely to be particularly useful for individuals suffering from depression. However, it is contraindicated in those who have experienced myocardial infarction or who have arrhythmias or severe liver disease. Thus, this medication is generally used only for those who fail with, have an adverse event in response to, or have a contraindication to one of the first-line medications [19] . Many smokers may also be averse to using a drug associated with treating psychiatric conditions.
Relative Ease of Use The dosing profile of nortriptyline is similar to those of varenicline and bupropion: one oral tablet of 25-100 mg per day or dosages titrated to serum levels recommended for depression.
e-Cigarettes
Electronic cigarettes (e-cigarettes) are battery-powered devices consisting of a cartomizer-usually containing a mixture of nicotine, water, flavourings and propylene glycol or glycerine-which produces a nicotine aerosol. Since e-cigarettes were first introduced into the market in 2003, there have been significant developments to make them more efficient and appealing [89] . Regulation of e-cigarettes varies widely from country to country. Many countries have banned them (e.g. Brazil, Canada, the Seychelles, Uruguay, Norway and Singapore), others have imposed heavy restrictions and some have licensed them as medicines [90, 91] (e.g. e-Voke in the UK, produced by British American Tobacco [92] ).
Relative Efficacy Only two randomized controlled trials have assessed e-cigarette use for smoking cessation, with a combined sample size of 662 participants. In both trials, early-generation devices with low levels of nicotine were used. Pooled data from these two randomized controlled trials showed that use of nicotine-containing e-cigarettes was associated with higher abstinence rates relative to placebo, comparable abstinence rates relative to NRT and a greater chance of reporting reductions in cigarette consumption of over 50 % [93] . Although further trials are needed [93] , similar efficacy has been noted in surveybased studies [93] [94] [95] [96] [97] .
Relative Safety There is no doubt that e-cigarettes are substantially less harmful than cigarettes, since they do not contain tobacco which, when lit, produces between 3000 and 4000 chemicals, many of which are carcinogenic [98] . Studies have identified a number of toxic chemicals in e-cigarette liquid (tobacco-specific nitrosamines and diethylene glycol [99] ; amino-tandalafil and rimonabant [100] ; carbonyls (formaldehyde, acetaldehyde and acrolein) [101] ; heavy metals (nickel, lead and cadmium) [101] ; silicate particles [102] ). However, the general consensus is that levels are low, unlikely to do harm and are substantially lower than those found in cigarettes-and in some cases, they are similar to those found in NRT (e.g. nitrosamines) [103] [104] [105] . Nonetheless, continuous monitoring is warranted, given the ever-changing product landscape.
Relative Cost A single disposable e-cigarette costs around £6 (US$9). Newer-generation starter kits cost anything from £17 to £90 (US$25 to 130), with a refill costing between £2 (US$3) and £4 (US$6) [106] , which is less expensive than, or as expensive as, purchasing NRT [107] .
Relative Use The presence of e-cigarettes in the UK market appears to have increased the number of smokers using non-tobacco nicotine-containing products [55] . Thus, it is likely that e-cigarettes are enticing new smokers to use smoking cessation aids rather than monopolizing the current medications market.
Relative Scope E-cigarettes are likely to be attractive for those smokers who miss the sensory and behavioural aspects of smoking. Currently available medicinal products, with the exception perhaps of some non-transdermal NRT, do not provide a sensation similar to that of smoking. E-cigarettes may be particularly suitable for those who have failed with other smoking cessation aids or for those for whom these aids are contraindicated.
Relative Ease of Use E-cigarettes provide the sensory and behavioural aspects commonly associated with smoking, i.e. the hand-to-mouth action. Smokers therefore often report that they are more satisfying than NRT, and so adherence is likely to be greater [108] . However, smokers must correctly change/fill cartridges, and charging is required for the new-generation products.
Clonidine
Given that anxiety is a symptom of nicotine withdrawal following smoking cessation [109] , it has been proposed that the anxiolytic clonidine, a noradrenergic agonist, may be a possible smoking cessation treatment [110, 111] .
Following evidence of its safety and efficacy, clonidine hydrochloride is now recommended as a second-line agent but is not approved by the US Food and Drug Administration (FDA) or any other drug regulatory body as a smoking cessation aid [112] .
Relative Efficacy Studies have shown that clonidine relieves cravings, anxiety, restlessness and tension [110, 111] , and it appears to promote smoking cessation, with beneficial effects particularly among those with high levels of anxiety [113] . A randomized clinical trial in 1988 with smokers who had failed in previous attempts to stop smoking reported that cessation success rates in clonidinetreated subjects, verified by serum cotinine concentrations, were more than twice those in placebo-treated participants [110] . In the same year, another randomized placebo-controlled trial with 40 cigarette smokers reported that clonidine treatment ameliorated short-term withdrawal symptoms, especially cravings, and that there was a trend towards a reduction in the number of cigarettes smoked [114] . However, another randomized trial with nearly 200 subjects failed to report a benefit in terms of withdrawal symptoms, quitting or smoking reduction in a primary care setting [115] .
Relative Safety Clonidine has adverse effects associated with its use: postural hypotension, dizziness, dry mouth, sedation, sleep disturbances, depression and constipation [113] . Although these are also classic withdrawal symptoms and may not result from drug use, this has resulted in avoidance of clonidine by many clinicians [116] .
Relative Cost Oral dosing of clonidine is relatively inexpensive (\$1 per day) in comparison with NRT or bupropion, which cost more than $3.00 per day [117] . Thus, if clonidine is deemed as effective as the first-line treatments, it is likely to result in a reduction in health care costs.
Relative Use Although clonidine is not currently licensed as a smoking cessation aid, and its side effects mean that is it unlikely to compete with the currently available first-line treatments, it is regarded as a secondline treatment in a number of countries.
Relative Scope Clonidine may be particularly useful for individuals with anxiety problems and may appeal to smokers who do not wish to use nicotine-based medications to make a quit attempt, or who have previously tried unsuccessfully to quit with other pharmacotherapy. However, many smokers are averse to using a drug associated with treating psychiatric conditions [109] . Caution is also advised when co-administering clonidine with beta blockers, calcium-channel blockers and digitalis [113] .
Relative Ease of Use The regimen is similar to that for the first-line treatments. Clonidine is also available as a patch, which may increase adherence rates [118] . Patch formulations of smoking cessation medications are discreet, provide a steadier supply of the drug and can be simpler to use than oral formulations.
Alternative Products with Unclear Efficacy
Venlafaxine
Rates of smoking are particularly high among individuals suffering from depression; thus, antidepressants may be a suitable pharmacotherapy for smoking cessation in such individuals [119] . Venlafaxine, a serotonin-noradrenaline reuptake inhibitor (SNRI), inhibits neural 5-HT, noradrenaline and dopamine reuptake, and is used in the treatment of depression and anxiety disorders [83] .
Relative Efficacy Preliminary evidence suggests that venlafaxine may have therapeutic effects when combined with NRT through its influence on improved memory and reduction in depressive symptoms [120] . In a study of nearly 150 smokers randomly assigned to receive venlafaxine plus NRT or placebo plus NRT in conjunction with behavioural counselling, venlafaxine did not appear to increase the propensity to quit smoking. However, this trial suggested that there may be benefits for lighter smokers, and a reduction in negative affect was noted [121] .
Relative Safety The side effects of SNRIs are greater than those of selective serotonin reuptake inhibitors (SSRIs) and bupropion; they include muscle spasms/ twitching, profuse sweating and dizziness [122, 123] . Controlled trials assessing the use of venlafaxine for the treatment of depression have noted excessive weight gain and sexual dysfunction [124] . Cardiac electrophysiological effects with venlafaxine have also been observed in guinea pig cardiac myocytes [125] . However, venlafaxine does have a more benign side-effect profile than older antidepressants.
Relative Cost The cost of 6 months of treatment with venlafaxine for depression is similar to that of bupropion at around £1530 (US$2210) [126] and therefore significantly more than the cost of NRT. Its cost effectiveness for smoking cessation and harm reduction has not been assessed.
Relative Use Venlafaxine's greater number of side effects means that it is unlikely to be licensed as a smoking cessation aid, unless its efficacy is proved to be substantially greater than that of first-line treatments.
Relative Scope Because of its antidepressant properties, venlafaxine may be an appropriate medication for individuals with co-morbid depression diagnoses. However, its inability to mimic the sensory and behavioural components of smoking, and its greater side effects in comparison with the medications discussed so far, may limit its use.
Relative Ease of Use Dosages of 75 to 375 mg/day administered as 2-or 3-times-daily regimens produce significant reductions in depression [127] . If similar dosages are used for smoking cessation, the regimen is more complex than the single daily dose of either varenicline or bupropion, but it is simpler than that of oral NRT.
nAChR Antagonists
Given the proven efficacy of varenicline, a partial agonist of nAChR, it has been suggested that nAChR antagonists may aid smoking cessation [128] . Such drugs include mecamylamine (trade name Inversine), currently approved for the management of hypertension; lobeline, an alkaloid derived from the leaves of an Indian tobacco plant (Lobelia inflate) [73, 129] ; GTS-21, a derivative of anabaseine (a product in tobacco), which improves cognitive function and may be a possible novel treatment for dementia [130] ; dianicline, a drug developed by Sanofi-Aventis, which has a pharmacological profile similar to that of varenicline; sazetidine, which is specified for the treatment of anxiety and depression; UCI-30002, a negative allosteric modulator of nAChR and an agonist of gamma-aminobutyric acid (GABA) receptors [131] ; and AT-1001 [N-(2-bromophenyl)-9-methyl-9-azabicyclo[3.3.1] nonan-3-amine], a high-affinity and highly selective ligand at the nAChR [132] .
Relative Efficacy Mecamylamine has shown some promising results [133] , particularly in women [134] . Lobeline has proved rather ineffective [73, 129] . The effects of GTS-21 on negative affect, cognition and smoking relapse are currently being investigated in a phase two clinical trial (ClinicalTrials.gov study ID NCT02432066). Some have argued that it may prove to be a better treatment option than the nicotine patch [135] and may be particularly beneficial for those with schizophrenia, as it appears to improve symptoms [136] . Clinical development of dianicline has been discontinued after reports of unfavourable results in phase 3 studies (Sanofi Pipeline, 2012). AT-1001 has been found to decrease nicotine selfadministration in rats and to be a potent partial agonist with 65-70 % efficacy at the human nAChR [137] . UCI-30002 has also been shown to decrease nicotine self-administration [138] .
Relative Safety Lobeline and mecamylamine have significant side effects [73, 129] , including drowsiness, hypotension and constipation [139, 140] . GTS-21 is no more toxic than nicotine and does not appear to affect either autonomic or skeletal muscle systems. Clinical trials suggest that it is well tolerated in large doses [130] . Dianiclin may have a more favourable profile than varenicline [41] , while sazetidine has fewer neurological side effects than other nicotinic agonists [141] .
Relative Cost The cost effectiveness of these products for smoking cessation has not been assessed.
Relative Use None of these products are licensed for smoking cessation, and many are in the early stages of clinical trials, thus it is not possible to predict the likely impact they may have in the future.
Relative Scope Mecamylamine was original marketed for lowering blood pressure, and so it may be particularly beneficial for individuals with certain cardiovascular conditions. It is easy to use and can be combined with NRT. In fact, the two therapies may offset each other's adverse effects [133, 140] . GTS-21 has been proposed as a possible treatment option for patients with schizophrenia [142] .
Relative Ease of Use Dosing is similar to that of bupropion and varenicline, with a recommended 8 mg tablet of lobeline once daily and a 150 mg twice-daily dose of GTS-21 (ClinicalTrials.gov study ID NCT02432066). However, many smokers are averse to using oral medication and prefer transdermal product forms.
Glucose Tablets
Oral dextrose (glucose) has been proposed as a possible aid for smoking cessation. It was hypothesized that glucose tablets could promote abstinence by satiating carbohydrate cravings, which ex-smokers often mislabel as cigarette cravings [143, 144] . Previous studies have shown that nicotine acts as an acute appetite suppressant by raising blood glucose levels and acting directly on cells in the lateral hypothalamus. The appetite suppressant effect may also be linked to the effects of nicotine on serotonergic pathways in the brain [143] .
Relative Efficacy In a randomized controlled trial with nearly 1000 participants, no significant effect of glucose tablets over and above sweet-tasting tablets was detected [144] . However, glucose tablets may promote short-term abstinence, particularly when used as an adjunct to NRT or bupropion [144, 145] .
Relative Safety Part of their appeal lies in their small number of side effects relative to the first-line treatments [143] . When used in small doses, no common side effects have been reported; however, at higher doses, allergic reactions have been noted, and their use in diabetic patients should be avoided.
Relative Cost The major advantage of glucose tablets is that they are relatively inexpensive; thus, they may be a treatment option in developing countries [143] .
Relative Use Given their lower cost and accessibility, the promotion of glucose tablets for smoking cessation would likely increase the overall use of smoking cessation medication, particularly in developing countries.
Relative Scope Glucose is unlikely to interact with other medications and so may be used concurrently [144] . It is freely available and has no contraindications (except that some caution should be advised for individuals with diabetes). This is important given that many smokers are treated with pharmacotherapy for smoking-related morbidities.
Relative Ease of Use Glucose tablets are freely available in shopping outlets, unlike bupropion and varenicline, which are available only on prescription. The recommended daily use is similar to that of NRT [144] .
Nicotine Vaccines
Vaccines targeting nicotine are being developed as a novel approach to treating tobacco dependence. The main mechanism of action is inducement of anti-nicotine antibodies, which bind to nicotine in the periphery and thus reduce the amount that enters the brain. Vaccines may also have a secondary effect of slowing the rate of nicotine delivery-an important property, as rapid increases in nicotine levels are more likely to lead to addiction than slow kinetics [146] . First-generation formulations were conjugate vaccines, consisting of nicotine linked to a carrier protein and then mixed with alum adjuvant [147] . Modifications and further developments have focused on finding the most effective site of attachment for nicotine, identifying the number of nicotine molecules that need to be linked to each carrier protein, and modifying the composition of the protein itself [147, 148] . To increase efficacy, support has been given to the use of multivalent vaccines, i.e. combinations of multiple vaccine products and concurrent use with other smoking cessation pharmacotherapy [149] . Animal studies have shown a strong synergistic effect of a nicotine vaccine in combination with the nAChR antagonist mecamylamine [150] .
Recently, the first synthetically engineered nanoparticle nicotine vaccine, SEL-068 (designed by Selecta Biosciences, Inc.), entered a phase 1 clinical trial for evaluation of its safety, tolerability and pharmacodynamic profile [151] . As it is fully synthetic, the immune response focuses on nicotine, thus avoiding responses to biological carriers. Alternatives to nicotine vaccines have also been suggested. These include passive immunization, which (unlike vaccines) does not require weeks to months for generation of effective levels of antibodies; and gene transfer, which involves administration of viral vectors containing genes for expression of drug-specific antibodies [152] .
Relative Efficacy First-generation nicotine vaccines were shown to clinically reduce the amount of nicotine reaching the brain and to reduce nicotine self-administration behaviours [153] [154] [155] [156] [157] [158] . However, these strong preclinical findings were not subsequently mirrored in clinical trials, with the overall efficacy for smoking cessation being similar to that of placebo vaccines [159] [160] [161] . This may have been a consequence of poor antibody production or vaccine composition. Many vaccines produce nicotine-specific antibody levels not much above 50-100 lg/mL, which provides binding capacity for at most one cigarette [147] . Subgroup analyses have shown that subjects with the highest serum antibody concentrations have double the smoking cessation rates of control subjects [160, 162] . It also appears that nicotine vaccine candidates that incorporate hapten enantiopurity may maximize efficacy in comparison with use of racemic nicotine hapten [163] . However, a recent study concluded that nicotine vaccines do not appear to improve the chances of smoking cessation when given in addition to varenicline and behavioural support [164] .
Passive immunization with drug-specific monoclonal antibodies has been shown to block nicotine [150] , while preclinical tests in monkeys immunized with increased doses of the synthetically engineered nanoparticle nicotine vaccine SEL-068 showed a robust and dose-dependent induction of high titres of anti-nicotine antibodies with a strong affinity for nicotine [165] . In a recent study, SEL-068 was shown to attenuate nicotine's discriminative stimulus effects in nicotine-experienced monkeys [166] .
Relative Safety The safety profile of vaccines has been confirmed in clinical trials and is likely to be similar to that of other medications, although further surveillance is warranted [167] . In view of the novelty of gene transfers and possible unanticipated toxicities, evidence of longterm safety will be necessary for their development to proceed.
Relative Cost Although a nicotine vaccination programme was not found to be cost effective for smoking prevention [168] , there is some suggestion that vaccines will be less expensive than other smoking cessation treatments [169] . Costs are likely to be higher for passive immunization vaccines, with the dosages required being 10-100 times those widely used to treat cancer or immune disorders [170] .
Relative Use The effect on overall effective medication use is unclear. However, given that the majority of smokers obtain medication over the counter [171] , the requirement for administration by a health care professional means that few smokers are likely to opt to use nicotine vaccines.
Relative Scope Nicotine vaccines may be suitable for smokers with contraindications to other smoking cessation medication. Long-term, the treatment regimen for vaccines is simple, and they may be preferable for those with poor adherence.
Relative Ease of Use Although multiple injections of the first-generation vaccines are required to be administered intravenously by a health care professional, they have a prolonged effect on the immune system (for 6-12 months). Passive immunization vaccines, in contrast, do not require weeks to months for generation of effective levels of antibodies.
Drugs that Affect GABA Transmission
Nicotine stimulates the release of a number of neurotransmitters, including GABA. Thus, it has been proposed that medications that affect GABA neurotransmission may be useful as pharmacological treatments for tobacco addiction [172, 173] . One example is topiramate, which inhibits glutamatergic neurotransmission, reduces fast inward voltage-gated sodium currents [174] and enhances GABAergic tone by direct action on GABA-A receptors [175, 176] . Topiramate is approved for the treatment of epilepsy and has been shown to be efficacious for bipolar disorder, post-traumatic stress disorder and eating disorders (e.g. see McElroy et al. [177] ). Low-dose topiramate has also been used in the treatment of alcohol dependence [178] . Three other drugs that may also offer some utility for smoking cessation include zonisamide, which is in the same class of medications (marketed as Topamax) [179] ; gabapentin, an antiepileptic drug, which acts on voltagegated calcium channels (particularly N-and L-types) and binds to GABA-B receptors to inhibit their function [180, 181] ; and tiagabine, a blocker of GABA reuptake (marketed as Gabitril) [182, 183] .
Use of baclofen, a selective GABA-B receptor agonist, was recently proposed for smoking cessation, in response to the observation of co-occurrence between alcohol and nicotine use. Approximately half of the population who are dependent on alcohol are smokers, 75 % of whom require treatment for both dependences [184, 185] . Up until that point, drugs to tackle both addictions had proved unsuccessful.
Relative Efficacy Studies have demonstrated the efficacy of topiramate for smoking cessation, particularly among men and alcoholic smokers [186] [187] [188] . An additional benefit may be the prevention of post-cessation weight gain [189] . In a recent 10-week trial, topiramate resulted in higher quit rates than a placebo and significant decreases in weight [190] . Zonisamide also appears promising. Its combination with varenicline increases smoking quit rates and decreases nicotine withdrawal and craving relative to varenicline alone [179] . Studies of tiagabine suggest that it may reduce the rewarding effects of nicotine and improve cognitive performance in abstinent smokers [182] .
A number of studies have provided clinical and preclinical evidence that baclofen is a successful treatment for both tobacco addiction and alcoholism [172, 191] . A recent randomized placebo-controlled pilot trial demonstrated a significant reduction in craving and smoking [192] , while another found that baclofen significantly increased the percentage of days of abstinence from alcohol and tobacco co-use [193] . A further trial was terminated because of difficulties in recruiting an appropriate sample (ClinicalTrials.gov study ID NCT01228994).
In preclinical trials, gabapentin was shown to attenuate withdrawal symptoms and increase short-term abstinence [194] . However, two small-scale trials reported that gabapentin showed little promise for treating smoking cessation [195, 196] . This was confirmed in a recent proof-of-concept pilot study [197] .
Relative Safety In general, the safety and tolerability of GABA-based drugs have been confirmed [192] . However, they may be liable to abuse [198] and have side effects, including sedation, dizziness, weakness and fatigue [192] . In a trial of 12 smokers treated with topiramate, additional side effects-including slurred speech, depressive symptoms and fatigue-were noted, and three subjects interrupted treatment because of intolerable symptoms [199] . Zonisamide is slightly better tolerated than topiramate and does not produce the negative cognitive effects that are evident following topiramate administration [200, 201] . However, individuals using antiepileptic drugs, such as tiagabine, may be at risk of developing severe neuropsychiatric symptoms [202] .
Relative Cost Topiramate and gabapentin cost less than £4 (US$6) per week in comparison with at least £9 (US$14) for NRT [203, 204] .
Relative Use It is currently unclear whether GABAbased drugs would increase the overall use of effective medication. Although cheaper than nicotine-containing products, they would likely not be available over the counter.
Relative Scope GABA-based drugs may be useful for smokers who wish to prevent post-cessation weight gain and may act as a concurrent treatment for epilepsy, migraines, some psychiatric conditions and eating disorders (the conditions for which they were originally indicated). Baclofen may be suitable for individuals with coexisting alcohol use disorders.
Relative Ease of Use Many GABA-based drugs, including baclofen, must be taken every 4-6 h and preferably with clinical supervision to ensure compliance [191] [192] [193] . Thus, they do not appear to be easier to use than currently available drugs that are administered orally. Although extended-release formulations have been produced for multiple sclerosis patients, these have not received approval for use in smoking cessation (ClinicalTrials.gov study ID NCT01457352).
Drugs that Affect NMDA Receptors Directly or Indirectly
The finding that one of the effects of nicotine on the body is at the level of N-methyl-D-aspartate (NMDA) receptors in the brain motivated investigations into drugs that affect these receptors. Four drugs that appear to directly affect NMDA receptors have been, or are currently being, assessed in clinical trials: memantine, a non-competitive, selective NMDA receptor antagonist used in the clinical treatment of dementia (ClinicalTrials.gov study ID NCT00136786 [still running]); GW468816, a competitive antagonist at the glycine site [205] ; and the NMDA receptor partial agonist cycloserine (ClinicalTrials.gov study ID NCT01062932 [completed in 2012]). Gabapentin (discussed already) also directly inhibits NMDA receptors and potentiates the effect of NMDA-channel blockers [206] [207] [208] . A further drug, N-acetylcysteine [209] , has an indirect effect through the release of glutamate from glia into the extrasynaptic space via the cysteine-glutamate antiporter [210] . This increased basal glutamate activates type 2/3 metabotropic glutamate receptors (also extrasynaptic), which suppresses the release of synaptic glutamate [211] , thereby reducing NMDA receptor activation. Furthermore, N-acetylcysteine is a precursor for gamma-glutamylcysteinslycine, which has been shown to potentiate NMDA receptor responses [212, 213] . N-Acetylcysteine also stimulates the release of dopamine [214] , which is argued to play a major role in drug addiction [215] .
Relative Efficacy Memantine has demonstrated some efficacy for other dependencies, including opioid use [216] . However, in a small study of 20 smokers, memantine failed to facilitate smoking reduction [217] . Despite preclinical data being promising for GW468816, no effect on relapse or lapse rates have been reported relative to placebo [205] . Initial studies on cycloserine provided some support for its use with cue exposure therapy in attenuating conditioned reactivity to smoking cues [218] , but further development hinges on the results from the clinical trial. Finally, a pilot study exploring the effect of N-acetylcysteine has shown encouraging trends [209] . A recent review on the potential role of N-acetylcysteine in the management of substance use disorders concluded that it shows promise in terms of safety, tolerability and potential efficacy for promoting abstinence from cocaine, nicotine and cannabis [219] .
Relative Safety Although higher-affinity NMDA-related drugs can produce severe adverse neurotoxic and psychogenic effects in humans, and lower-affinity drugs are likely to have a greater number of side effects than NRT, data across a range of clinical applications have shown that NMDA-based drugs are safe and well tolerated [220] .
Relative Cost NMDA-related drugs are a similar price to NRT. For example, 28 tablets of memantine 10 mg costs around £35 (US$40) [221] .
Relative Use It is currently unclear whether NMDArelated drugs would increase the overall use of effective medication. However, if they were only available on prescription, their use would be unlikely to cannibalize the NRT market.
Relative Scope NMDA-related drugs were initially indicated for Alzheimer's disease, having a significant positive effect on cognition and behaviour. NMDA-based drugs also have anti-anxiolytic and antidepressant effects, so they may be a suitable treatment for smokers suffering from mood disorders [222] .
Relative Ease of Use Drugs targeting NMDA receptors are administered orally but generally require only one tablet per day. Dosing routines are therefore simpler than those for oral NRT but similar to those for varenicline and bupropion. However, many smokers are averse to using oral medication and prefer transdermal product forms.
Dopamine Agonists
As mesocorticolimbic dopamine systems mediate the reinforcement effects of nicotine [223] , researchers have hypothesized that drugs traditionally used to treat Parkinson's disease and appetite control disorders, which affect dopamine receptors, may be potential targets. Viable candidates for clinical investigation are levodopa [224] , bromocriptine, GSK598809, the cognate analogue GSK618334 and BP1.4979, developed by the BioProject.
Relative Efficacy Preliminary evidence in rats suggests that levodopa may aid in preventing post-cessation weight gain by diminishing dopaminergic responses to external stimulation [225] . Levodopa does not appear to promote abstinence or withdrawal symptom relief [224] . Bromocriptine has been shown to decrease cigarette craving and reduces smoking rates in humans [226, 227] .
Animal studies have shown that GSK598809 decreases nicotine-seeking behaviour and nicotine cravings [228] . Phase 1 and 2 trials have since been conducted with human participants, but with mixed results. One clinical trial found that a 75 mg dose alleviated cravings in smokers after 14 h of overnight abstinence. It also partially reversed attentional bias, though such effects were not maintained at later time points (ClinicalTrials.gov study ID NCT00437840 [completed in 2008] ). In another trial, which included a placebo control group, a single dose of GSK598809 did not reduce the reinforcing value of smoking and nicotine after measurement using the Behavioural Economic Task and Cigarette Choice Paradigm. In fact, when smokers were allowed to smoke freely, those who had received the active drug had higher cigarette consumption, suggesting some compensatory behaviour (ClinicalTrials.gov study ID NCT00605241 [completed in 2012]). GSK598809 was also recently tested in a third trial as an add-on to cognitive behavioural therapy and an NRT patch for the prevention of very early relapse from smoking in severe chronic smokers (ClinicalTrials.gov study ID NCT01188967 [completed in 2014] ). Because of the potential cardiovascular liability at high doses, each patient in the trial was required to use an ambulatory monitor, which was a significant hurdle to recruitment. [completed in 2011] ). These focused on its safety profile and pharmacokinetics, showing promising results. However, the drug has yet to be tested as a smoking cessation aid. A phase 2 clinical trial assessing the efficacy and safety of BP1.4979 for smoking cessation was completed at the beginning of 2015 (ClinicalTrials.gov study ID NCT01785147), but the results have yet to be published.
Relative Safety Many new drugs that target dopamine receptors have possible cardiovascular liability at high doses. Suitable data on the safety profiles of drugs that target dopamine receptors are currently unavailable. The side effects of bromocriptine and levodopa have hindered their recommendation for smoking cessation [229] .
Relative Cost The potential costs of these new drugs that target dopamine receptors are unclear. Previous studies have reported that dopamine agonists cost significantly more than other medications that have been tested as smoking cessation aids [230] .
Relative Use It is unclear whether these novel drugs that target dopamine receptors will increase the overall use of smoking cessation aids. Currently, the evidence regarding efficacy is mixed, which, in addition to their likely high cost, may hinder their use.
Relative Scope New drugs targeting dopamine receptors may be effective for those with Parkinson's disease and for individuals who wish to prevent post-cessation weight gain [231] .
Relative Ease of Use New drugs targeting dopamine receptors are available in dosages of 60-175 mg tablets. Thus, the regimen will likely consist of one tablet per day, which is less than that for oral NRT. However, many smokers may not wish to use oral medication and prefer transdermal product forms.
Noradrenaline Reuptake Inhibitors
Preclinical and clinical studies suggest that noradrenaline contributes to mediation of the subjective effects of tobacco [232] . The noradrenaline reuptake inhibitor atomoxetine (marketed as Strattera), used in the treatment of attention deficit disorder, may thus be a useful aid for smoking cessation [233] . Atomoxetine causes noradrenergic augmentation in the prefrontal cortex [234] . The alphaand beta-adrenergic receptor blockers carvedilol (marketed as Coreg and Dilatrend) and labetalol have also been suggested as harm reduction treatment options for tobacco dependence, given that they may dampen the cardiovascular response to nicotine [235] . Reboxetine, a selective noradrenaline reuptake inhibitor prescribed as an antidepressant, was also advocated as a possible treatment option [236] . Although reboxetine received preliminary approval by the FDA in 1999 as an antidepressant because of its positive pharmacological profile and lack of side effects, its development has been halted [237] .
Relative Efficacy Trials using clinical populations (psychiatric patients, non-psychiatric patients and patients with attention deficit-hyperactivity disorder) have shown tentative support for the possibility that atomoxetine may reduce cigarette consumption and/or smoking behaviours [233, 238, 239] . In healthy populations, atomoxetine has been found to reduce the number of cigarettes smoked but does not result in lower salivary cotinine levels than placebo [240] . A recent randomized controlled trial that aimed to assess atomoxetine's effects on nicotine response and stress response in smokers was suspended because of a lack of funding (ClinicalTrials.gov study ID NCT02046551).
Treatment with carvedilol and labetalol has been found to attenuate nicotine-induced increases in the heart rate and blood pressure [241, 242] . Attenuation of tobacco withdrawal symptoms has been noted with high-dose labetalol treatment relative to placebo [242] . In contrast, the use of carvedilol alone or in combination with nicotine lozenges does not appear to affect withdrawal symptoms [241] . Carvedilol may also aid in the treatment of the physiological effects of smoking cessation, such as tremor and cough, by preventing or suppressing mucus hypersecretion [243] .
Use of reboxetine has been found to attenuate nicotine self-administration in rats by over 60 % [244] and to result in an adaptive modification of the function of selective noradrenaline transporters [245] . A patent has been approved to assess the use of an effective amount of reboxetine in combination with administration of a smoking cessation-enhancing agent (e.g. NRT and an opioid antagonist) [246] .
Relative Safety As atomoxetine does not raise concentrations of dopamine in the prefrontal cortex, it has low abuse potential-a finding that has been supported in clinical trials [234] . However, it is not well tolerated by healthy adults at high doses [240] . There are several clinical situations in which atomoxetine should be closely monitored or not taken, including in pregnant women and in patients who have a history of narrow-angle glaucoma, cardiovascular problems, epileptic seizures, Tourette's syndrome or urinary obstruction [247] . Carvedilol is also contraindicated for a long list of conditions, including (but not limited to) bradycardia, sick sinus syndrome, hepatic dysfunction, obstructive airways disease, severe hypotension, metabolic acidosis and phaeochromocytoma [248] . The safety and efficacy of once-daily carvedilol (25 or 50 mg) appear to be comparable to those of twice-daily labetalol (200 or 400 mg) [249] . Reboxetine is well tolerated by adults and the elderly during short-and long-term treatment for depression [250] .
Relative Cost On the assumption that one 40 mg tablet of atomoxetine would be taken for 21 days [240] , the cost would be in excess of £45 (US$65) per smoker for a 3-week period [251] , which is similar to the costs of many of the first-line treatments. Carvedilol and labetalol are much cheaper, at around £0.06 per day (US$0.09) [252] .
Relative Use It is unclear whether any of these drugs will increase the overall use of smoking cessation aids. However, given the current lack of evidence for their efficacy, they are unlikely to monopolize the smoking cessation market.
Relative Scope Given their original indications, atomoxetine may be beneficial for individuals suffering concurrently with attention deficit disorder, and carvedilol may be beneficial for those with mild to severe congestive heart failure or left ventricular dysfunction, and following a heart attack. However, there are several contraindications which need to be considered.
Relative Ease of Use One tablet once or twice daily reflects the dosing profile of the first-line treatments varenicline and bupropion. However, many smokers are averse to using oral medication and prefer transdermal product forms.
PPARc Agonists
Downregulation of pulmonary epithelial peroxisome proliferator-activated receptor gamma (PPARc) by cigarette smoke promotes inflammatory pathways and contributes to the pathogenesis of chronic obstructive pulmonary disease (COPD). Thus, it has been proposed that PPARc agonists, such as pioglitazone (Actos) and OMS405 (originally OMS403), may be suitable pharmacotherapy for harm reduction [253] .
Relative Efficacy A preclinical trial of OMS405 for smoking withdrawal was conducted in the USA in 2009, and a phase 2 clinical trial was conducted in 2010 [254] . Although the results have yet to be released, the patent literature reports a decrease in smoking behaviour in a manner similar to that seen with varenicline [255] . There is also evidence for a possible harm reduction indication for the drug. PPARc agonists reverse the downregulation of PPARc through a number of pathways and help to improve symptoms of COPD, a disease that is largely due to smoking [256] . PPARc agonists are currently also being assessed for their possible chemoprotective effects in relation to lung cancer [257] .
Relative Safety OMS405 appears to have a good safety profile and can be used concurrently for the treatment of diabetes [258] . Water retention is a common side effect with other PPARc-based drugs, and the licensing advises caution when using them in patients diagnosed with cardiac disorders. Their safety relative to that of other smoking cessation aids is currently unclear [259] .
Relative Cost A daily dose of OMS405 30 mg costs around £9 (US$13) per week, which is similar to the cost of NRT but cheaper than varenicline [260] .
Relative Use It is unclear whether OMS405 will increase the overall use of smoking cessation aids. If it is less expensive and provides protective effects against inflammation, it may have potential as a harm reduction product.
Relative Scope OMS405 was initially indicated for metabolic diseases and thus may be a suitable treatment option for smokers diagnosed with diabetes.
Relative Ease of Use OMS405 involves a daily 30 mg dose, which is an easier routine than those for oral NRT products. However, many smokers may be averse to using oral forms and prefer transdermal products.
Lorcaserin
Lorcaserin hydrochloride (marketed as Belviq and Lorqess) was approved in June 2012 by the FDA as an adjunct to a reduced-calorie diet and physical activity for chronic weight management. It is believed that lorcaserin decreases food consumption and promotes satiety by selectively activating 5-HT receptors in the brain [261] . It may thus be a suitable pharmacotherapy for smokers wishing to prevent post-cessation weight gain. A patent has recently been submitted to create a nutritional supplement for smoking cessation, in which it is proposed that lorcaserin may be a main ingredient with the aim of increasing 5-HT levels and assisting in maintaining body weight [262] . In addition, lorcaserin used alone or in combination with varenicline may be a novel agent for smoking cessation, given that 5-HT systems play key roles in the action of nicotine [263] .
Relative Efficacy In preclinical studies, lorcaserin was found to decrease nicotine self-administration and nicotineenhanced responding with conditioned reinforcement in rats [263] [264] [265] . A recent phase 2 clinical trial found that lorcaserin was associated with a significantly higher continuous quit rate than placebo. In addition, a reduction in bodyweight was also observed [266, 267] . A further phase 2 clinical trial is currently being conducted to assess the effects on urges to smoke, withdrawal symptoms and the reinforcing effects of smoking and eating behaviour, in addition to body weight and abstinence (ClinicalTrials.gov study ID NCT02044874).
Relative Safety Treatment with lorcaserin is well tolerated, with the most commonly observed adverse reactions being headache, dizziness, fatigue, nausea, dry mouth and constipation [266, 267] . However, neuropsychiatric and cognitive-related adverse events are frequent and, although no imbalance in reported cancer incidence in smokers has been seen, mammary tumours have been found in rats treated with lorcaserin [268] .
Relative Cost Lorcaserin has not been deemed a costeffective weight loss strategy, and costs substantially more (US$1750 for the full treatment) than traditional smoking cessation aids [269] .
Relative Use The overall effect on effective medication use is unclear, but the high costs will likely limit its distribution.
Relative Scope Lorcaserin may be suitable for smokers who wish to prevent post-cessation weight gain. However, there are several adverse side effects which need to be considered.
Relative Ease of Use The tested lorcaserin dosage in one clinical trial was 10 mg once or twice daily, which is similar to the dosing regimens for other smoking cessation medications [266] . It is currently only available in oral form, which may not be suitable for all smokers.
Alternative Products: No Efficacy
Other Anxiolytics
Given the evidence for clonidine, other anxiolytics have been proposed as possible aids for smoking cessation, including buspirone (trade name Buspar), a non-benzodiazepine anxiolytic with effects on 5-HT neurotransmission; ondansetron (trade name Zofran), a 5-HT 3 receptor antagonist; and diazepam (first marketed as Valium) and meprobamate (marketed as Miltown and Equanil among others), which are tranquillizers. Beta blockers also have potential anxiolytic effects and have been advocated as smoking cessation aids. The idea behind the use of anxiolytics is that they moderate the anxiety experienced with withdrawal symptoms and increase the main neural transmitters that play a major role in nicotine dependence [109] .
Relative Efficacy As a whole, the findings from clinical trials suggest that these medications have little effect on smoking cessation [83, 109] . For example, the rate of smoking abstinence has been reported to range from 36 to 88 % and from 16 to 89 % in buspirone and placebo treatment groups, respectively. However, these medications may have some effects on urges to smoke [270] . In a randomized double-blind placebo-controlled trial, with 40 long-term cigarette smokers, buspirone ameliorated shortterm withdrawal symptoms associated with smoking cessation [271] , while animal studies have demonstrated that ondansetron is effective in decreasing cravings [272] . Research into the utility of anxiolytics has in recent years diminished because of the claim that the role of anxiety in smoking may have been overplayed [109] .
Relative Safety Although many of these medications have significant side effects, such as risks of abuse and sedation [5] , some have more favourable profiles. Buspirone has been advocated, as it lacks abuse liability and does not promote dependence [273] . In a double-blind placebo-controlled trial with around 100 smokers, 4 weeks of treatment with ondansetron was not associated with any severe side effects [274] . In 984 patients with generalized anxiety disorder who received buspirone in double-blind studies, the incidence of drowsiness did not differ significantly from that reported in placebo recipients [275] . Side effects that have occurred significantly more frequently include dizziness, headache, nervousness, light-headedness, paraesthesia and excitation [275] .
Relative Cost It is likely that these products will be a similar price to clonidine and therefore cheaper than NRT [117] . A recent cost-effectiveness analysis of treatments for anxiety disorders found that benzodiazepines (like buspirone) were more cost effective than tricyclic antidepressant drugs [276] .
Relative Use Given their lack of efficacy and side effects, there is little justification for licensing them as smoking cessation aids.
Relative Scope These products may be particularly useful for individuals with anxiety problems and may appeal to smokers who do not wish to use nicotine-based medications to make a quit attempt, or who have previously tried unsuccessfully to quit with other pharmacotherapy.
Relative Ease of Use The regimen is likely to be similar to those of other first-line prescription medications, such as bupropion. Unlike NRT, anxiolytics are available only in oral form and so may not be suitable for all smokers.
SSRIs
The SSRIs fluoxetine, paroxetine, sertraline, citalopram and zimeledine (which are first-line treatments for depression) have been proposed as possible smoking cessation aids, given that dysphoria, depressed mood and a history of major depressive disorder are related to uptake of smoking and failed attempts to quit [119] . The neurotransmitter 5-HT also plays a major role in nicotine's addictive effects [277] .
Relative Efficacy Long-term trials of SSRIs and some short-term trials have failed to show efficacy in relation to smoking cessation among smokers with and without a diagnosis of depression [83, 278, 279] , although there is some evidence to support the efficacy of sequential treatment (16 weeks of treatment starting 8 weeks prior to quitting) relative to standard treatment (10 weeks of treatment starting 2 weeks prior to quitting) [280] . A randomized placebo-controlled trial found no evidence that fluoxetine treatment, when used as an adjunct to NRT, was effective, but it did find that there may be an advantage to using it in depressed patients [281] . In another study, sertraline treatment reduced self-reported withdrawal symptoms and resulted in less irritability, anxiety and restlessness than placebo; however, abstinence rates did not differ [282] .
Relative Safety Some side effects have been reported with the use of SSRIs for smoking cessation, particularly at high doses, including amblyopia (dimness of sight), gastrointestinal disorders, nausea, palpitations and tremors [281, 283] . Treatment with SSRIs has also been associated with emotional detachment, although controversy still exists on this issue [284] . SSRIs may have slightly more side effects than bupropion, including sexual dysfunction and weight gain [284] .
Relative Cost There are currently no reports on the cost effectiveness of SSRIs for smoking cessation; however, they do appear to be more cost effective than the tricyclic antidepressants mentioned above when they are used to treat depression [285] [286] [287] .
Relative Use SSRIs' lack of efficacy for smoking cessation relative to the first-line treatment bupropion means that they are unlikely to be licensed for use as aids for smoking cessation.
Relative Scope Given that SSRIs are first-line treatments for depression, they may be particularly suitable for smokers with a co-morbid diagnosis. However, their lack of efficacy means that they are unlikely to be indicated for such purposes. Many smokers may also be averse to using a drug associated with treating psychiatric conditions.
Relative Ease of Use The dosing regimens for SSRIs are similar to those for other antidepressants, including bupropion. However, unlike NRT, they are available only on prescription and do not address the sensory and behavioural components of smoking.
Silver Acetate
Use of silver acetate for smoking cessation is analogous to use of disulfiram for alcoholism, being based on the principles of aversive conditioning. It works by producing an unpleasant metallic taste in the mouth when used in combination with smoking [288] .
Relative Efficacy Although a possible effect in promoting cessation has not been disproved, any such effect is likely to be small and less than that of NRT [288] . In a randomized trial of over 500 participants, abstinence rates were higher in the silver acetate group than in participants receiving nicotine gum or ordinary gum, but only among those with a lower weighted pack-year consumption [289] .
Relative Safety Excessive ingestion causes a rare condition called argyrism. Thus, a dose no greater than 756 mg is recommended [288] . In randomized controlled trials, side effects appear to be similar to those of NRT and are generally mild and transient, with the most common one being mouth irritation [289] .
Relative Cost Its lack of efficacy means it is unlikely to be a cost-effective product for smoking cessation.
Relative Use Failure to show a beneficial impact on smoking cessation, its mechanism of action and concerns over safety mean that silver acetate is highly unlikely to be licensed as a smoking cessation aid.
Relative Scope A particularly appealing aspect of silver acetate for smokers is its availability in lozenge, gum and spray forms; however, its main mode of action-aversive taste-may be unappealing to some. There are also limits on the length of time for which it can be used, with the need to avoid argyrism [288] .
Relative Ease of Use Use is similar to that of NRT: a 2.5 mg lozenge, 1.6 mg gum or 756 mg spray used up to six times per day for 3-6 weeks. This dosing frequency is considerably greater than those for bupropion and varenicline and may thus adversely affect adherence rates.
Nicobrevin
Nicobrevin contains four 'active' ingredients (quinine, menthyl valerate, camphor and eucalyptus) and has been claimed to provide sensory relief following smoking cessation [290] . There does not appear to be a clear mechanism of action for the use of menthyl valerate as a component of an anti-smoking preparation [291] . There is some evidence that cigarette smoking may have an effect on quinine pharmacokinetics [292] , while oral camphor has been claimed to have carminative properties, and eucalyptus is often used as a decongestant [291] .
Relative Efficacy There is no long-term evidence that use of Nicobrevin can aid smoking cessation, and there is insufficient evidence to support the efficacy of any of the four ingredients it contains [290, 291] . Although it may be the case that it has effects on the respiratory and digestive systems, which may relieve some of the symptoms that smokers experience when quitting, any such benefits are eroded by the slightly higher relapse rates in actively treated groups [291] . There have been no clinical trials comparing the use of Nicobrevin with use of first-line treatments.
Relative Safety Concerns have been raised over the health implications of excessive quinine consumption in cigarette smokers [291] . Toxicity with camphor has been reported, while eucalyptus consumption is associated with nausea and vomiting [291] . Side effects associated with Nicobrevin include visual problems, skin irritation and convulsions [291] .
Relative Cost In a number of countries, Nicobrevin is no longer available as a smoking cessation aid, and there is no evidence on its cost effectiveness.
Relative Use Around 1 million packs of Nicobrevin were sold between 1992 and 1997. This number dropped to 6600 packs between 2003 and 2008, while just 200 packs were sold in the subsequent 2 years [291] . Following concerns over its safety, it has since been withdrawn in a number of countries, including the UK [291] .
Relative Scope Its lack of efficacy and withdrawal from the market in a number of countries mean that it is unlikely to be a suitable aid for smoking cessation.
Relative Ease of Use Its oral formulation and dosing regimen mean that it is easier to use than some NRT products; however, some smokers may be averse to taking medication orally. A 28-day course of 10 mg tablets is generally recommended, starting with one pill in the morning and two at night.
Modafinil
Modafinil is marketed as a wakefulness-promoting agent for individuals who experience excessive sleepiness, including narcolepsy [293] . Its mechanism is elusive but involves stimulation of the histamine, noradrenaline, 5-HT, dopamine and orexin systems in the brain [294] .
Relative Efficacy Modafinil has demonstrated significant efficacy in cocaine dependence [147] , and studies have shown its potential for alleviating tobacco withdrawal symptoms [295] . Subsequently, it was assessed for the treatment of smoking cessation [296] , but the trial was terminated because of the detrimental effect of the drug. In the trial, quit rates did not differ between individuals who received modafinil and those who received a placebo, while smoking consumption was 44 % higher in non-abstainers in the intervention arm. In another study, modafinil alone or in combination with nicotine lozenges did not affect tobacco withdrawal symptoms [297] , although preliminary results from another study suggested that combining modafinil with transdermal NRT could provide complementary effects [298] .
Relative Safety Modafinil increases heart rate and systolic blood pressure, so is likely to be contraindicated for individuals with cardiovascular disease. In one randomized crossover trial with 19 participants, increases in negative affect and withdrawal symptoms were noted [299] .
Relative Cost A course of modafinil costs around £120 (US$170) compared with around £165 (US$240) for varenicline. Modafinil is thus substantially more expensive than a course of NRT and so is unlikely to be deemed cost effective, given its lack of efficacy [300] .
Relative Use As modafinil has significant side effects and lower efficacy than traditional smoking cessation aids, it is unlikely to be licensed as an aid for smoking cessation or harm reduction.
Relative Scope Modafinil may be suitable for smokers who also suffer from sleep disorders (its original indication), but it may be contraindicated for those with cardiovascular disease.
Relative Ease of Use Dosing usually requires a daily load of 200 mg. Thus, the dosing regimen is easier than that for oral NRT but is similar to those for bupropion and varenicline. Some smokers may, however, be averse to taking medication orally.
MAOIs
One factor that may account for the association between depression and smoking is monoamine oxidase (MAO), an enzyme first discovered over 40 years ago. Tobacco smoke contains MAO inhibitors (MAOIs), which act synergistically with nicotine to enhance addition potential. This is evidenced by smokers having lower levels of MAO than non-smokers [301] . Thus, it has been proposed that MAOIs-such as moclobemide, selegiline, lazabemide and EVT302-may have synergistic beneficial effects on depression and smoking cessation.
Relative Efficacy Trials of moclobemide and selegiline, when combined, have failed to show efficacy for smoking cessation [83] . However, genetic markers in cholinergic loci in the 15q24 chromosomal region have been proposed to affect response; thus, it may be possible to identify individuals who are likely to benefit from treatment [302] .
Relative Safety MAOIs are contraindicated with bupropion use [303] . Selegiline is well tolerated by smokers [304] and does not have any serious adverse effects [302, 304] . In a recent double-blind parallel-group trial with over 200 smokers, selegiline compliance was high, and there was no evidence of an effect on depressive symptoms [305] . When moclobemide is taken in doses similar to those used to treat depression, the major side effect is insomnia [306] .
Relative Cost Given their lack of efficacy, MAOIs are unlikely to be a cost-effective treatment options for smoking cessation. Patch formulations of selegiline cost approximately US$600/month for treatment, which is substantially more than the cost of SSRIs [307] .
Relative Use Given the lack of current evidence of their efficacy, it is unlikely that MAOIs will be licensed for smoking cessation. They are also not a first-line treatment option for depression.
Relative Scope If MAOIs had been shown to be effective, they would be appropriate for individuals with a comorbid depression diagnosis, and they have fewer side effects than other antidepressants [83] .
Relative Ease of Use A transdermal form for selegiline, approved for the treatment of depression by the FDA, may be appropriate for individuals averse to oral formulations [302] .
Opioid Antagonists
The promotion of the opioid antagonists naltrexone, naloxone and buprenorphine was based on the idea that the reinforcing properties of nicotine may be mediated by release of neurotransmitters, which have an impact on the endogenous opiate system [308] . Naloxone is routinely administered to reverse the effects of narcotic overdose, and naltrexone is administered to blunt certain effects of narcotics, while buprenorphine reduces withdrawal symptoms following opioid discontinuation. A controlled-release formulation of naltrexone is approved to treat opioid and alcohol dependence in the USA [309] .
Relative Efficacy Research to date suggests that opioid antagonists do not promote smoking cessation, while the results are mixed for effects on withdrawal symptoms, the hedonic effects of smoking and cigarette consumption [308] . However, generally positive effects on post-cessation weight gain have been reported [310] . Concurrent use of buprenorphine and bupropion does not significantly increase abstinence from tobacco, opioids or cocaine, relative to buprenorphine alone [311] .
Relative Safety Common side effects of opioid antagonist administration include sedation, dizziness, nausea, constipation and vomiting. Physical dependence and addiction are also clinical concerns [312] . Less frequent side effects include perceptual distortion, respiratory depression and myoclonus [313] .
Relative Cost Opioid antagonist costs and availability vary widely in both developing and developed countries. The median cost of opioid antagonists, as a percentage of the gross national product (GNP) per capita per month, is 36 % in developing nations and 3 % in developed nations [314] . Their cost effectiveness for smoking cessation is relatively unknown; however, given their lack of efficacy to date, they are unlikely to be more cost effective than first-line treatments.
Relative Use The current lack of evidence for their efficacy in relation to smoking cessation, and concerns over possible dependence and side effects, mean that they are unlikely to be licensed as smoking cessation aids.
Relative Scope Opioid antagonists may be particularly beneficial for individuals who are concurrently dependent on cigarettes and opioids (e.g. morphine, heroin and codeine), but they are associated with a number of side effects.
Relative Ease of Use The dosage regimens for opioid antagonists are similar to those for varenicline and bupropion. For example, one oral tablet of naltrexone between 25 and 200 mg per day has been recommended [312] . However, many smokers are averse to using oral medication and prefer transdermal product forms.
Selective Cannabinoid Type 1 Receptor Antagonists
Rimonabant and taranabant, which are selective cannabinoid-1 receptor antagonists, might restore imbalance in food intake and energy expenditure, which is often altered in smokers [229] . Although they were initially considered by medicines regulatory agencies for both weight loss and smoking cessation [315] , rimonabant and taranabant were withdrawn from the US market primarily because of adverse neuropsychiatric effects [316] .
Relative Efficacy Rimonabant and taranabant appear to increase the chances of quitting smoking, and they may moderate weight gain, but the evidence is inconclusive regarding long-term abstinence [317] . Clinical trials of rimonabant, which began in 2002, have also noted increased high-density lipoprotein (HDL) cholesterol levels and decreased triglyceride levels [318] .
Relative Safety In 2008, both rimonabant and taranabant were withdrawn by their manufacturers because of links with mental disorders and unacceptable side effects, including digestive, nervous, psychiatric, skin and blood vessel disorders [319] . Other side effects include headache, diarrhoea, insomnia and sinusitis.
Relative Cost There is no evidence for the cost effectiveness of these products in relation to smoking cessation, because of their withdrawal from the market.
Relative Use Both rimonabant and taranabant have been withdrawn by their manufacturers because of their adverse side effects [319] . For weight control, rimonabant has been argued to be within the range of what is generally regarded as cost effective [320] .
Relative Scope Rimonabant and taranabant may be suitable for smokers who wish to prevent post-cessation weight gain, although their side effects are likely to erode any benefits.
Relative Ease of Use In previous studies, rimonabant was used in a dosage of 20 mg once daily [317, 319] , which is similar to the dosages recommended for other first-line treatments requiring a prescription. However, many smokers are averse to using oral medication and prefer transdermal product forms.
Supplements (SAMe and St John's Wort)
Two supplements have been suggested as possible aids for smoking cessation as a consequence of their effects on biological compounds associated with the addictive effects of nicotine. The first, S-adenosyl-L-methionine (SAMe), is proposed to have antidepressant properties by causing elevations in dopamine and noradrenaline levels and increases in 5-HT turnover [321] . The second, St John's wort, is proposed to be a treatment for mild depression because (1) it inhibits reuptake of norepinephrine, dopamine and 5-HT; and (2) it has an affinity for adenosine and GABA receptors [83, 322] . However, the utility of SAMe and St John's wort as treatments for depression has been questioned, given the lack of evidence for their efficacy relative to placebo [323] , likely in part because of their poor bioavailability following oral administration [324] [325] [326] .
Relative Efficacy Two small trials of St John's wort failed to detect significant effects on quit rates or withdrawal symptoms [327, 328] ; although there may be some worthwhile benefits in preventing weight gain [327] . One trial of SAMe did not find significantly increased tobacco abstinence rates nor decreased nicotine withdrawal symptoms in comparison with placebo [329] , and evidence is lacking for a dose response [83] .
Relative Safety Treatment with SAMe up to 1600 mg/day for 6 weeks appears to be safe, well tolerated and without serious side effects [330] . St John's wort is not associated with adverse events but is contraindicated for concurrent contraceptive use and has mild side effects, including anxiety, dizziness, abdominal bloating and dry mouth [328, 331] .
Relative Cost SAMe is relatively expensive in comparison with NRT, with prices for a 200 mg tablet ranging from $0.75 to $1.25 [332] . St John's wort is generally lower in price than other antidepressants, such as bupropion [333] ; thus, if it had been deemed effective, it might have been a suitable option for developing countries.
Relative Use SAMe and St John's wort are both available over the counter; however, their lack of efficacy for smoking cessation means that they are unlikely to increase overall use of treatments during smoking cessation.
Relative Scope These products may be suitable for individuals who are averse to prescription pharmacotherapy and who have contraindications to the other medications discussed in this review. They are also well tolerated and have fewer side effects.
Relative Ease of Use In clinical trials SAMEe has been used in formulations of four 400 mg tablets daily and St John's wort in three 300 mg tablets daily [328, 329] . This may adversely affect treatment adherence relative to the firstline treatments, which require just one oral dose per day.
Other Tricyclic Antidepressants
Following the success of bupropion and nortriptyline, other tricyclic antidepressants have been advocated, including doxepin and imipramine [83] . Doxepin's structure and general pharmacological properties are similar to those of imipramine and bupropion, but it also combines a sedative effect with antidepressant activity. Consequently, doxepin is generally used for individuals with sleep disturbance or depression associated with anxiety.
Relative Efficacy There have been no long-term studies of doxepin and imipramine, but short-term trials have suggested that imipramine does not significantly reduce cigarette consumption in comparison with a no-medication control [334] . Although doxepin reduces cravings, the rates of sustained abstinence at 2 months are similar to those seen with placebo [335] .
Relative Safety Doxepin is generally well tolerated, with side effects similar in nature to those of other tricyclic antidepressants (e.g., dry mouth, drowsiness and constipation) [336] . Doxepin tends to cause fewer side effects than imipramine [336, 337] and is well tolerated in elderly subjects with cardiovascular disease. However, although doxepin causes fewer cardiovascular side effects than other antidepressants, it has intrinsic cardiotoxicity on overdosage [336] .
Relative Cost The cost of smoking cessation support with imipramine and doxepin would likely be similar to that of treatment with other antidepressants [338] . It has been suggested that doxepin tablets are one of the cheapest treatment options for depression [339] .
Relative Use Although these products were once widely used as antidepressants, they have subsequently been replaced by newer antidepressant medications with better side-effect profiles [83] .
Relative Scope As with bupropion, tricyclic antidepressants are likely to be particularly useful for those suffering from depression. However, their side effects would likely limit their use, and many smokers may be averse to using a drug associated with treating psychiatric conditions.
Relative Ease of Use The dosing profiles of tricyclic antidepressants are similar to those of varenicline and bupropion; however, many smokers are averse to using oral medication to help them quit smoking.
Conclusion
National guidelines around the world recommend use of evidence-based aids for tobacco dependence to help smokers to quit and/or to reduce their cigarette consumption (e.g. England, America, Brazil, Uruguay and China) [340] [341] [342] [343] . This includes a combination of behavioural support and pharmacotherapy [344, 345] . For example, in England, specialist stop-smoking services, commissioned by local authorities, offer smokers face-to-face counselling in addition to three first-line medications: NRT, bupropion or varenicline [344] . Although these have shown substantial efficacy, particularly when used in conjunction [346] , calls have been made to increase their diversity [6, 347, 348] . This paper reviewed evidence for novel pharmacotherapies, contrasting them with the first-line treatments, using six criteria (ESCUSE). Many of these medications are in early development, and clinical trials have yet to be completed, thus the conclusions on impact, efficacy and safety are limited. It does not appear that any single medication will serve as a panacea to effectively reduce smoking across the population, given that tobacco dependence reflects a complex interplay of neurobehavioral, genetic, environmental and social factors [349] .
Where evidence is available, cytisine appears to offer one of the best prospects for the future, having established safety and efficacy, and being very inexpensive. Electronic cigarettes have become very popular in some countries, but their efficacy and long-term safety require further consideration. Nicotine vaccines and galenic formulations of varenicline may show promise if they produce higher antibody levels and reduce side effects, respectively, while lorcaserin may prevent post-cessation weight gain. Harm reduction benefits have been reported for several products, including carvedilol and labetalol treatment, which have been found to attenuate nicotine-induced increases in heart rate and blood pressure.
It has been argued that a major obstacle to the development of new smoking cessation and harm reduction medications is inefficient early clinical evaluations, with the vast majority of drugs failing to show efficacy for cessation after significant resources and time have been wasted. This may be combated by more efficient designs (e.g. those that recruit only motivated smokers, have shorter outcome measures and use crossover methods) [350] . Pharmaceutical companies also tend to focus research spending on the development of the next 'blockbuster' drug. Perhaps as researchers we should instead maintain focus on those products with proven safety and efficacy and assess how these can be used more widely and effectively. One way to increase effectiveness is through improved use and adherence-for example, via free provision or reimbursement schemes [351, 352] and tackling misperceptions about smoking cessation medication [353] . Many misperceptions arise from the information provided with smoking cessation medications, which by highlighting potential risks fails to educate smokers that these pale by comparison with the real-world documented risks of tobacco use [354] . Practice guidelines for nicotine dependence also only recommend that medication be integrated with behavioural support [19] , while combined use of transdermal NRT and oral NRT, varenicline and NRT, and varenicline and bupropion, appears to result in significant benefits over sole use of any product [81, [355] [356] [357] [358] [359] .
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